Literature DB >> 17619167

Marked thrombocytosis during treatment with ceftazidime for pulmonary infection.

Huang-Chi Chen1, Cheng-Yuan Wang, Chuan-Sheng Wang.   

Abstract

When an infected patient suffers from thrombocytosis, it is very difficult to identify beta-lactam antibiotic induced cases of the disease and separate these from the possibility that the disease is an acute-phase reaction in the infected patient. We present the case of a 54-year-old man who was treated with ceftazidime for pneumonia and developed thrombocytosis during the treatment course. Thrombocytosis persisted until ceftazidime was discontinued, despite clinical and radiological evidence showing that the pneumonia had greatly improved. The Naranjo probability scale indicates ceftazidime as the possible cause of the thrombocytosis in our patient. Although no obvious complications occur in most patients, we should pay close attention to the possibility of adverse reactions and evaluate whether the infection is treated with the appropriate antibiotics.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17619167     DOI: 10.1007/s11096-007-9145-8

Source DB:  PubMed          Journal:  Pharm World Sci        ISSN: 0928-1231


  9 in total

Review 1.  Thrombocytosis.

Authors:  Andrew I Schafer
Journal:  N Engl J Med       Date:  2004-03-18       Impact factor: 91.245

2.  A method for estimating the probability of adverse drug reactions.

Authors:  C A Naranjo; U Busto; E M Sellers; P Sandor; I Ruiz; E A Roberts; E Janecek; C Domecq; D J Greenblatt
Journal:  Clin Pharmacol Ther       Date:  1981-08       Impact factor: 6.875

Review 3.  Thrombosis and haemorrhage in polycythaemia vera and essential thrombocythaemia.

Authors:  M A Elliott; A Tefferi
Journal:  Br J Haematol       Date:  2005-02       Impact factor: 6.998

4.  Incidence and etiology of thrombocytosis in an adult Turkish population.

Authors:  Timucin Aydogan; Mehmet Kanbay; Ozlem Alici; Ali Kosar
Journal:  Platelets       Date:  2006-08       Impact factor: 3.862

5.  Extreme thrombocytosis: what are the etiologies?

Authors:  Viroj Wiwanitkit
Journal:  Clin Appl Thromb Hemost       Date:  2006-01       Impact factor: 2.389

6.  Thrombocytosis during antifungal therapy of candidemia.

Authors:  Angela D Saathoff; Stephanie L Elkins; Stanley W Chapman; Susan Fleming McAllister; John D Cleary
Journal:  Ann Pharmacother       Date:  2005-05-24       Impact factor: 3.154

7.  The incidence of thrombotic and hemorrhagic disorders in association with extreme thrombocytosis: an analysis of 129 cases.

Authors:  D H Buss; J J Stuart; G E Lipscomb
Journal:  Am J Hematol       Date:  1985-12       Impact factor: 10.047

Review 8.  Drug-induced thrombocytosis.

Authors:  J L Frye; D F Thompson
Journal:  J Clin Pharm Ther       Date:  1993-02       Impact factor: 2.512

9.  Thrombocytosis: an acute-phase reactant, not an adverse reaction to the new beta-lactam antibiotics.

Authors:  M F Parry; B Jacobs; B Scully; H C Neu
Journal:  Diagn Microbiol Infect Dis       Date:  1984-06       Impact factor: 2.803

  9 in total
  2 in total

1.  Unfractionated heparin as a safe alternative in a case of low molecular weight heparin-induced thrombocytosis: A case report.

Authors:  Salem Jabira; Hassan Mitwally; Mohamed Saad; Edin Karic; Khaled Gazwi; Hani Elzeer; Moustafa Elshafei
Journal:  Ann Med Surg (Lond)       Date:  2021-04-30

2.  Correlation between bone metastasis and thrombocytosis in pulmonary adenocarcinoma patients.

Authors:  Wei Zhang; Chao Yu; Bin Huang; Feng-Liang Zhou; Hai-Dong Huang; Qiang Li
Journal:  Oncol Lett       Date:  2014-12-04       Impact factor: 2.967

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.